Lung Cancer

Maker of experimental cancer drug lowers dosage

Published in Cancer Weekly, November 11th, 2003

The maker of an experimental lung cancer drug says it lowered the dosage used in clinical trials after a few gravely ill patients taking the drug died earlier than expected.

In a news release and conference call with analysts, Cell Therapeutics, Inc., (CTI) officials said fewer than 10 patients had died after their infection-fighting white blood cells were destroyed in the tests. Company officials would not give the exact number of deaths.

The patients who died had a median life expectancy of 10 weeks; the company did not say at what point in their treatment they died. It also would not say how many more patients died while being administered the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-11-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry